

Anaerobe Cumulative Antibiogram	Antimicrobial Agents						
	Ampicillin/sulbactam	Cefoxitin	Clindamycin	Meropenem	Metronidazole	Moxifloxacin	Piperacillin/tazobactam
<i>Bacteroides fragilis</i>	84	100	26	93	100	61	96
<i>Prevotella species</i>	97	—	69	98	99	66	100
<i>Fusobacterium species</i>	100	—	77	100	95	68	96
Anaerobic gram-positive cocci	—	—	97	100	100	72	99
<i>Propionibacterium acnes</i>	—	—	53	—	0	95	100
<i>Clostridium perfringens</i>	100	—	83	100	100	83	100
<i>Clostridium species (not perfringens)</i>	—	—	67	100	100	62	94

Reference:
CLSI M100 34th edition
Isolates collected from selected US hospitals from Jan. 1, 2013, to Dec. 31, 2016.

Common Indications for Empiric Vancomycin

Febrile Neutropenia

- High risk (refer to NCCN or IDSA guidelines for criteria) with severe cephalosporin allergy
- Suspected serious catheter-related infection, SSTI, pneumonia, hemodynamic instability, blood culture with gram-positive cocci, or previous MRSA infection/colonization

Community-Acquired Pneumonia (CAP)

- Severe CAP (ie: admitted to ICU) PLUS hospitalized with IV antibiotics within prior 90 days
- Prior respiratory isolation of MRSA

Hospital-acquired (HAP)/ventilator-associated (VAP) Pneumonia

- Prior respiratory isolation of MRSA
- Empyema
- Risk factors for resistance or mortality
 - HAP: mechanical ventilation, septic shock, IV antibiotics within 90 days
 - VAP: acute respiratory distress syndrome prior to VAP, septic shock at time of VAP, IV antibiotics within 90 days, acute renal replacement therapy prior to VAP, ≥ 5 days in hospital prior to VAP

Skin and Soft Tissue Infection (SSTI)

- Severe purulent infection or presence of abscess
- Non-purulent infection with one of the following:
 - Severe cephalosporin allergy
 - MRSA risk (penetrating trauma, MRSA infection elsewhere or nasal colonization, injection drug use, severely immunocompromised)
 - Necrotizing fasciitis
 - ICU admission for SSTI

Diabetic Foot Infection (DFI)/Chronic Wound

- Any indications listed within SSTI section
- Severe or chronic-moderate
 - Moderate: deeper than skin & subcutaneous tissues, no signs of systemic inflammatory response syndrome (SIRS)
 - Severe: SIRS OR presence of ischemia
- ICU admission for DFI or chronic wound

Scan QR Code
for a full list of
indications



SMH Levofloxacin Guidelines for Use

- CAP when B-lactam allergy present
- HAP/VAP: As 2nd agent if dual pseudomonas coverage indicated
- Acute exacerbation of COPD
- MDR organism
- Pseudomonas if po agent needed
- UTI when B-lactam allergy present (acute uncomplicated cystitis in women)
- UTI if complicated/male
- Prostatitis
- Pyelonephritis step-down
- Gram-negative (excluding pseudomonas) bacteremia step-down if po agent needed
- Intra-abdominal infection
- Uncomplicated febrile neutropenia
- Leukemia antibiotic prophylaxis
- Surgical prophylaxis if B-lactam allergy

2024

Antimicrobial Agent Susceptibilities

PROVIDED BY

Microbiology
217-788-3057

Pharmacy
217-788-3010



701 N. First St. • Springfield, IL 62781

Percent Susceptible – All Inpatients

Jan. 1–Dec. 31, 2023 Inpatient isolates only, first isolate per patient	# Isolates	Percent Susceptible																		
		Ampicillin (\$\$–IV) (\$–PO)	Ampicillin/sulbactam (\$\$)	Cefepime (\$\$)	Ceftazidime (\$\$)	Ceftriaxone (\$)	Clindamycin (\$\$–IV) (\$–PO)	Erythromycin (\$\$)	Gentamicin (\$\$)	Levofloxacin (\$–IV) (¢–PO)	Linezolid (\$\$–IV) (\$–PO)	Meropenem (\$\$\$)	Nitrofurantoin (\$)	Oxacillin (\$\$)	Penicillin-G (\$\$)	Piperacillin-Tazobactam (\$\$)	Tetracycline	TMP/SMX (\$\$–IV) (¢–PO)	Tobramycin (\$)	Vancomycin (\$\$)
GRAM-NEGATIVE BACILLI		Percent Susceptible																		
<i>Escherichia coli</i>	866	54	65	100	95	90	R		92	72			97	R	R	96		78	92	R
<i>Klebsiella pneumoniae</i>	325	R	77		93	90	R		94	87			32	R	R	96		87	92	R
<i>Klebsiella oxytoca</i>	102	R	67	100	95	89	R		94	94			84	R	R	98		89	93	R
<i>Proteus mirabilis</i>	246	81	93		99	96	R		95	64			R	R	R	100	R	78	95	R
<i>Enterobacter cloacae</i>	130	R	R	99			R		99	95			71	R	R			95	99	R
<i>Enterobacter aerogenes</i>	50	R	R	98			R		100	94			20	R	R			100	100	R
<i>Serratia marcescens</i>	62	R	R	100	100	98	R		100	90			R	R	R			98	90	R
<i>Citrobacter freundii</i>	47	R	R	100			R		96	98			97	R	R			91	96	R
<i>Morganella morganii</i>	41	R	R	96	80	78	R		85	61			R	R	R	100		61	98	R
<i>Pseudomonas aeruginosa</i>	398	R	R	89	91	R	R			77		91		R	R	84	R	R	97	R
<i>Acinetobacter baumannii</i>	35	R	83	63	49		R		89	77		80		R	R	62		89	91	R
<i>Stenotrophomonas maltophilia</i>	45	R	R			R	R		R	89		R		R	R	R		96	R	R
GRAM-POSITIVE COCCI		Percent Susceptible																		
<i>Staphylococcus aureus</i> §	586	R					69	43			100		55			89	97		100	
<i>Staphylococcus aureus</i> (MRSA)	274	R					61	16			100		0			84	96		100	
<i>Staphylococcus aureus</i> (MSSA)	333	R					75	66			100		100			93	98		100	
<i>Staphylococcus epidermidis</i>	139	R					53	29			100		29			67			100	
<i>Staphylococcus lugdunensis</i>	29	R					73	73			100		83			92			100	
<i>Enterococcus faecalis</i> *	150	99		R	R	R	R				100							R	R	95
<i>Enterococcus faecium</i> *	101	8		R	R	R	R				100							R	R	21
<i>Streptococcus agalactiae</i> *	29	100				100	33				100				100					100
<i>Streptococcus pyogenes</i> **	50	100				100	31	23			100				100					100
<i>Streptococcus pneumoniae</i>	42					88 [†]									55 [†]					
					100 [†]		35				100				100 [†]			67		100

Percent Susceptible – ICU

Jan. 1–Dec. 31, 2023 ICU isolates only, first isolate per patient	# Isolates	Percent Susceptible																			
		Ampicillin	Ampicillin/sulbactam	Cefepime	Ceftazidime	Ceftriaxone	Clindamycin	Erythromycin	Gentamicin	Levofloxacin	Meropenem	Nitrofurantoin	Oxacillin	Penicillin-G	Piperacillin-Tazobactam	Tetracycline	TMP/SMX	Tobramycin	Vancomycin		
GRAM-NEGATIVE BACILLI		Percent Susceptible																			
<i>Escherichia coli</i>	134	54	66	100	96	92	R		97	70			99	R	R	93		79	96	R	
<i>Klebsiella pneumoniae</i>	60	R	82	100	97	95	R		97	93			R	R	R	90		89	97	R	
<i>Proteus mirabilis</i>	30	83	97		100	97	R		90	60		R	R	R	100	R		77	90	R	
<i>Enterobacter cloacae</i>	27	R	R	100	67	67	R		100	89	100	55	R	R				96	100	R	
<i>Pseudomonas aeruginosa</i>	60	R	R	82	83	R	R			82	88		R	R	83	R		R	98	R	
<i>Acinetobacter baumannii</i>	13	R	92	77	69		R		92	92	92		R	R	77		100	100	R	R	
GRAM-POSITIVE COCCI		Percent Susceptible																			
<i>Staphylococcus aureus</i> §	97	R									71	47						58			
																			94	97	
																					99

KEY

- * Sterile sites only
- ** Combined isolates from 2020–2023
- R Intrinsic resistance
- § First staphylococcus aureus isolate per patient
- † Meningitis interpretations
- ‡ Non-meningitis interpretations

COST

- ¢ < \$1
- \$ = \$1–\$10
- \$\$ = \$10–\$50
- \$\$\$ = \$50–\$100
- \$\$\$\$ = \$100–\$200
- \$\$\$\$\$ > \$200